

S 1225

Greater Access to Affordable Pharmaceuticals Act

Congress: 108 (2003–2005, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Jun 10, 2003

Current Status: Committee on Health, Education, Labor, and Pensions. Ordered to be reported without amendment favora

Latest Action: Committee on Health, Education, Labor, and Pensions. Ordered to be reported without amendment favorably. (Jun 11, 2003)

Official Text: <https://www.congress.gov/bill/108th-congress/senate-bill/1225>

Sponsor

Name: Sen. Gregg, Judd [R-NH]

Party: Republican • **State:** NH • **Chamber:** Senate

Cosponsors (4 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Kennedy, Edward M. [D-MA]	D · MA		Jun 10, 2003
Sen. McCain, John [R-AZ]	R · AZ		Jun 10, 2003
Sen. Schumer, Charles E. [D-NY]	D · NY		Jun 10, 2003
Sen. Miller, Zell [D-GA]	D · GA		Jun 23, 2003

Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Markup By	Jun 11, 2003

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
108 HR 2491	Identical bill	Jun 25, 2003: Referred to the Subcommittee on Courts, the Internet, and Intellectual Property.

Greater Access to Affordable Pharmaceuticals Act - Amends the Federal Food, Drug, and Cosmetic Act to: (1) limit a brand name drug manufacturer to one Food and Drug Administration (FDA) 30-month stay of competition in a patent infringement suit against a generic drug applicant; (2) permit a generic applicant being sued to file a counterclaim to correct or delete patent information; (3) limit damages that a brand name manufacturer may recover in an instance where such manufacturer failed to file certain patent information; (4) permit a generic drug applicant to seek declaratory judgment regarding patent infringement prior to marketing a drug; (5) forfeit the 180-day market exclusivity period for a first generic drug applicant to a subsequent generic applicant if the first applicant engages in certain activities which impede such drug's timely marketing; and (6) permit alternative means to determine bioequivalence for drugs that are not absorbed into the bloodstream.

Actions Timeline

- **Jun 11, 2003:** Committee on Health, Education, Labor, and Pensions. Ordered to be reported without amendment favorably.
- **Jun 10, 2003:** Introduced in Senate
- **Jun 10, 2003:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.